Table 1 Cohort demographics
From: Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Cohort | Group | N (F/M) | Age, median (IQR) | N, APOE ε4 +/−a | Aβ1–42 ng/L, median (IQR) | P-tau181 ng/L, median (IQR) | T-tau ng/L, median (IQR) |
|---|---|---|---|---|---|---|---|
Pilot study | Control | 24 (8/16) | 72 (62–74) | – | 833 (714–998) | 42 (36–51) | 288 (218–320) |
AD | 19 (9/10) | 76 (71–81)b | – | 390 (351–456)c | 92 (81–104)c | 940 (710–1090)c | |
Clinical study I | Stable MCI | 15 (6/9) | 67 (59–76) | – | 1200 (880–1500) | 54 (40–59) | 230 (190–320) |
Prodromal AD | 10 (7/3) | 66 (59–74) | – | 380 (270–480)d,e | 96 (77–160)f,g | 690 (510–1100)f,g | |
AD | 6 (2/4) | 70 (57–79) | – | 400 (330–460)d | 98 (81–120)g,h | 600 (540–860)g,h | |
PD | 10 (5/5) | 60 (54–68) | – | 850 (580–1000) | 34 (24–48) | 140 (110–180) | |
Clinical study II | Control | 44 (30/14) | 75 (68–78) | 10/17 | 890 (660–1100) | 45 (38–53) | 320 (270–390) |
AD | 36 (23/13) | 73 (67–77) | 25/10 | 380 (300–440)i,j | 74 (65–100)g,i | 680 (510–870)g,i | |
PD | 11 (6/5) | 69 (68–76) | – | 660 (430–910) | 37 (33–47) | 220 (170–320) |